ReviewJournal of endocrinological investigation2026
Advances in proteomics research related to semaglutide: evidence from humans and animals.
Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWith the advancement of proteomics technologies, an increasing number of studies have begun to examine semaglutide-associated protein expression changes and pathway alterations across different biological contexts. However, existing evidence remains fragmented across different disease backgrounds, sample types, and research platforms, lacking systematic integration.
methodsThis review searched PubMed, Embase, and Web of Science for relevant studies published as of April 2026, including population-based, animal, and in vitro model studies that implemented semaglutide interventions and reported proteomic results.
resultsA total of 16 studies were ultimately included, comprising 4 population-based studies and 12 animal and in vitro model studies. The included studies examined both circulating samples and tissue-level specimens, including serum, plasma, adipose tissue, myocardium, aorta, lung, kidney, hippocampus, and skeletal muscle. Common proteomics platforms utilized included SomaScan, TMT-LC-MS/MS, DIA proteomics, phosphorylation proteomics, and mitochondrial proteomics. Multiple studies identified the PPAR signaling pathway, oxidative phosphorylation, and fatty acid metabolism as frequently occurring pathways, while ECM remodeling, complement/inflammatory pathways, and mTORC1 signaling were also observed in some studies. These results suggest that semaglutide is associated with proteomic changes across metabolic, cardiovascular, hepatic, pulmonary, renal, and nervous systems, with recurring signals involving fatty acid metabolism, mitochondrial function, inflammatory protein networks, and extracellular matrix-related pathways.
conclusionOverall, proteomic evidence provides a useful molecular framework for describing semaglutide-associated biological responses across multiple tissues. However, existing studies still have limitations such as small sample sizes, high subject heterogeneity, significant differences in proteomic platforms, and limited population studies. Therefore, future research will require larger sample sizes, standardized designs, and multi-omics integration studies to further determine which proteomic signatures are reproducible, biologically meaningful, and clinically translatable.
Indexed as
Identifiers
42489869What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.